Anavex starts 30mg dose step in Alzheimer’s drug Phase 1 trial

The trial which intended to establish the maximum tolerated single dose, safety and pharmacokinetics of ANAVEX 2-73 is being conducted in Germany in partnership with ABX-CRO.

In the trial, the subjects are given single, ascending oral doses of ANAVEX 2-73 with one group advancing to a maximum single oral dose of 240mg.

Study’s primary objective is to investigate the safety and tolerability of ANAVEX 2-73 in human for the fist time, while the secondary objective of the trial is to establish the pharmacokinetic profile of single oral ascending doses of ANAVEX 2-73.

Prior to that, the company has concluded third of six dose steps and follows the successful completion of the 1mg and 10mg dosing rounds.